Research programme: Ebola immunotherapeutics - Emergent BioSolutions

Drug Profile

Research programme: Ebola immunotherapeutics - Emergent BioSolutions

Alternative Names: Anti-Ebola monoclonal antibody - Emergent Biosciences; Ebola hyperimmune product - Emergent BioSciences; Modified vaccinia Ankara Ebola Zaire vaccine; MVA EBOZ; MVA-Ebola vaccine - Emergent BioSciences

Latest Information Update: 22 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Emergent BioSolutions
  • Class Monoclonal antibodies; Viral vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ebola virus infections

Most Recent Events

  • 20 Jul 2015 Emergent Biosolutions awarded BARDA for the development of Ebola monoclonal antibodies
  • 06 Mar 2015 Preclinical trials in Ebola virus infections in USA before March 2015 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top